

## **AdvanceCOR Successfully Starts a Clinical Phase II Trial with Revacept® for the Treatment of Ischemic Stroke**

*Martinsried/Munich, Germany, April 2013* -- AdvanceCOR GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of cardiovascular diseases, announced the start of a Phase II clinical trial with the peptide drug Revacept®. Revacept® has been developed for the therapy of ischemic stroke. The trial was initiated, and the first patients have been recruited. So far, drug administration has been well tolerated by these patients, no relevant side effects occurred. The same was true in all subjects in a previous phase I trial.

The trial is designed as a multicentric, randomized, double blind, placebo-controlled study, and is conducted in several specialized university centres in Germany. Patients with ischemic stroke or transient ischemic attack (TIA) receive Revacept® once at a dose of either 40 mg or 120 mg, or matching placebo. Primary end point is the occurrence of micro-embolic signals (MES) which correspond to small thrombi (blood clots), and which are found in patients' brain arteries (as assessed by ultrasound Doppler investigation). Secondary end points include brain imaging by NMR, major adverse events, clinical testing and neurological status assessment, and measurement of platelet aggregation.

"We are very much looking forward to the results of this trial," said Götz Münch, CEO of AdvanceCOR. "The trial is to show proof of concept for treatment with Revacept® in patients with this disease condition."

Revacept® is a polypeptide with a unique mode of action. It is developed by AdvanceCOR for the treatment of ischemic stroke and other atherosclerotic diseases. Revacept® is a drug which potently inhibits the initial steps of platelet activation without affecting general hemostasis, corresponding to a large and currently unmet medical need, and a billion-sized market.

In contrast to existing anti-platelet drugs, Revacept® does not result in any effect on general hemostasis which incurs a relevant bleeding risk with these existing drugs.

### **Notes to Editors**

#### **About REVACEPT®:**

AdvanceCOR's lead product Revacept® is a lesion-specific inhibitor of arterial thrombosis for the treatment of patients with acute coronary syndromes and stroke. Revacept has the unique feature to potently inhibit the initial steps of platelet activation without affecting general hemostasis.

Revacept® has a prolonged half-life - effects are maintained for about 2 weeks after single dosing. Revacept® has been validated in relevant animal models and has shown strong efficacy to reduce thrombus formation at vascular lesions and plaques, and to improve the outcomes of stroke (clinical symptoms as well as histological measurement of lesion size).

#### About AdvanceCOR GmbH

AdvanceCOR GmbH is a privately owned biotechnology company located in Martinsried near Munich, Germany. AdvanceCOR develops drugs which focus on inflammatory mechanisms in atherosclerosis and vascular disease. AdvanceCOR owns 3 different projects generated from its own scientific program or from the outstanding university groups of the company's founders.

#### About MIG AG

MIG Verwaltungs-AG with operations in Munich, Germany is the initiator of the MIG funds, a series of venture capital funds for private investors with the investment focus in German speaking countries. MIG was founded end of 2004 by successful entrepreneurs and has more than EUR 800 million under management in their funds. MIG is among the most active Venture Funds in German speaking countries.

For more information please contact

AdvanceCOR GmbH  
Prof. Dr. Götz Münch  
Fraunhoferstr. 17  
D-82152 Martinsried  
Germany  
phone +49-89-8565-2010  
Email: [info@advanceCOR.com](mailto:info@advanceCOR.com)

MIG Verwaltungs AG  
Michael Motschmann  
Ismaninger Straße 102  
D-81675 München  
Germany

Email: [info@mig.ag](mailto:info@mig.ag)